Application Note

< Previous         Next >  
IPPC: an interactive platform for prostate cancer multi-omics data integration and analysis
Xiongjun Ye1,† , Fujun Peng2,3,† , Jun Liu1 , Haiyue Zhao1 , Weinan Chen1 , Huanrui Wang1 , Peng Zhang4,* , Xiaobo Huang1,*
1Urology and Lithotripsy Center, Peking University People’s Hospital, Beijing 100034, China
2Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
3Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences, Suzhou 215123, China
4University of Maryland School of Medicine, Baltimore, MD 21201, USA
These authors contributed equally to this work.
*Correspondence to:Peng Zhang , Email:peng.zhang@ihv.umaryland.edu Xiaobo Huang , Email:huang6299@sina.com
J Mol Cell Biol, Volume 13, Issue 5, May 2021, Pages 383-385  https://doi.org/10.1093/jmcb/mjab004

Prostate cancer is a clinically heterogeneous disease and remains the most common non-skin malignancy in men worldwide (Abate-Shen and Shen, 2000; Litwin and Tan, 2017), which is often diagnosed through screening with digital rectal examinations and quantitation of serum levels of prostate-specific antigen (PSA). At the morphological aspect, the Gleason scoring system is regarded as the most reliable and predictive histological grading system (Welch and Albertsen, 2009; Heidenreich et al., 2011). Interpatient genomic heterogeneity in prostate cancer is well recognized; however, molecular stratification of prostate cancer to guide treatment selection based on predictive genomic biomarkers remains an unmet clinical need (Prensner et al., 2012; Topalian et al., 2016).